More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the ...

Investors looking for a way to pump up their passive income streams want to turn their attention toward the pharmaceutical ...

Stocks knocked down in the first ten months of the year often suffer further damage as people sell for tax losses. But they ...

On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...

BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...

The BBC reported that AstraZeneca and Pfizer are credited with together saving more than 12 million lives in the first year ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Pfizer (PFE – Research Report), with a price target ...

Is Pfizer stock a sell after shares skidded on the news Trump selected Kennedy to take over HHS? Is PFE stock now a sell? Billionaire Israel Englander Is Selling Nvidia and Palantir and Buying a ...

The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...

The findings of a study into the effect of COVID-19 vaccines on children are being misrepresented in posts shared on social ...

The presumptive new CDC director, Dave Weldon, is a known vaccine safety skeptic. In contrast, the FDA choice — Johns Hopkins ...

Acoramidis becomes the second drug ever approved for this condition, based on the results of the ATTRibute-CM trial.